Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Fish and Richardson
Argus Health
Chubb
Citi
Moodys
Cerilliant
Dow
Express Scripts

Generated: December 14, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR REVLIMID

« Back to Dashboard

Clinical Trials for Revlimid

Trial ID Title Status Sponsor Phase Summary
NCT00056160 CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple Myeloma Completed Celgene Corporation Phase 3 Randomized subjects will receive CC-5013 plus high-dose dexamethasone or placebo appearing identical to CC-5013 plus high-dose dexamethasone in 4-week cycles. Each subject will participate in a treatment phase and a follow-up phase.
NCT00067743 A Study of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed Celgene Corporation Phase 2 This is a multicenter, open-label study in adult subjects with Type 1 Complex Regional Pain Syndrome. Subjects diagnosed with unilateral Type 1 CRPS will be enrolled sequentially to receive CC-5013 10 mg/day orally. For each subject the study consists of two phases: Pre-treatment phase(1 wk) and treatment phase (12 wks)
NCT00087672 A Phase II Study of CC-5013 in Myelofibrosis Completed Celgene Corporation Phase 2 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
NCT00087672 A Phase II Study of CC-5013 in Myelofibrosis Completed M.D. Anderson Cancer Center Phase 2 The goal of this clinical research study is to learn if CC-5013 (lenalidomide) can help to control myelofibrosis. The safety of lenalidomide in the treatment of myelofibrosis will also be studied.
NCT00093028 Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II Completed University of Arkansas Phase 3 The purpose of this study is - to find out the effects of treating patients with two new chemotherapy drugs (bortezomib and Revlimid™), - to study how many patients' myeloma responds to treatment on this study, and how many patients survive after this treatment, - to learn if a patient's genetic makeup before and after treatment can predict which patients will respond to bortezomib and Revlimid™, and to learn more about how the body responds (gene array studies).
NCT00098475 Lenalidomide and Dexamethasone With or Without Thalidomide in Treating Patients With Multiple Myeloma Active, not recruiting National Cancer Institute (NCI) Phase 3 This randomized phase III trial studies lenalidomide and low-dose dexamethasone to see how well it works compared to lenalidomide and standard-dose dexamethasone, given with or without thalidomide, in treating patients with multiple myeloma. Biological therapies, such as lenalidomide, may stimulate the immune system in different ways and stop cancer cells from growing. Lenalidomide and thalidomide may also stop the growth of multiple myeloma by blocking blood flow to the cancer. Drugs used in chemotherapy, such as dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving lenalidomide, thalidomide, and dexamethasone together may kill more cancer cells.
NCT00100880 Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Completed National Cancer Institute (NCI) Phase 1 This phase I trial is studying the side effects and best dose of lenalidomide in treating young patients with recurrent, progressive, or refractory CNS tumors. Lenalidomide may stop the growth of CNS tumors by blocking blood flow to the tumor. It may also stimulate the immune system in different ways and stop tumor cells from growing.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Revlimid

Condition Name

Condition Name for Revlimid
Intervention Trials
Multiple Myeloma 104
Chronic Lymphocytic Leukemia 32
Lymphoma 22
Leukemia 16
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Revlimid
Intervention Trials
Multiple Myeloma 172
Neoplasms, Plasma Cell 169
Lymphoma 104
Leukemia 78
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Revlimid

Trials by Country

Trials by Country for Revlimid
Location Trials
Canada 120
Spain 48
France 48
Germany 47
Italy 46
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Revlimid
Location Trials
Texas 96
New York 85
California 83
Ohio 73
Florida 66
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Revlimid

Clinical Trial Phase

Clinical Trial Phase for Revlimid
Clinical Trial Phase Trials
Phase 4 1
Phase 3 49
Phase 2/Phase 3 3
[disabled in preview] 379
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Revlimid
Clinical Trial Phase Trials
Completed 120
Active, not recruiting 106
Recruiting 93
[disabled in preview] 122
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Revlimid

Sponsor Name

Sponsor Name for Revlimid
Sponsor Trials
Celgene Corporation 171
National Cancer Institute (NCI) 88
M.D. Anderson Cancer Center 50
[disabled in preview] 87
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Revlimid
Sponsor Trials
Other 392
Industry 340
NIH 91
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Federal Trade Commission
Harvard Business School
Fuji
Argus Health
Cantor Fitzgerald
Cerilliant
Dow
US Army
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.